Literature DB >> 3874175

Augmentation of interleukin 1 and interleukin 2 production by OK-432.

O Ichimura, S Suzuki, M Saito, Y Sugawara, N Ishida.   

Abstract

Intraperitoneal (i.p.) administration of OK-432 augmented both interleukin 1 (IL-1) and interleukin 2 (IL-2) production to the rechallenge of OK-432 in vitro. Peritoneal exudate cells (PEC) of mice 8 days after i.p. injection with OK-432 (1 KE/mouse) showed maximum IL-1 production to the restimulation with OK-432 in vitro. OK-432-induced IL-1 was consisted of three molecular weight species (two major peaks: 85 K and 15 K daltons and one minor peak: 67 K daltons) on Sephadex G-100 chromatography. Splenocytes of mice 4 days after i.p. injection with OK-432 (1 KE/mouse) demonstrated maximum IL-2 production to the in vitro rechallenge of OK-432, however, in vivo OK-432 administration failed to enhance ConA-induced IL-2 production in vitro. From gel filtration analysis, OK-432 induced IL-2 had an unique molecular weight (approximately 70 K daltons). From these results, OK-432-induced augmentation of cellular immunity against tumor cells might be due to the activation of so-called lymphokine cascade reaction mediated by IL-1 and IL-2.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874175     DOI: 10.1016/0192-0561(85)90035-9

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  13 in total

1.  Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.

Authors:  M Saito; O Ichimura; M Kataoka; Y Moriya; K Ueno; Y Sugawara; M Nanjo; N Ishida
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis.

Authors:  H Fukui; C W Reynolds; B Lenz; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Autoimmune kidney disease in MRL/Mp-lpr/lpr mice inhibited by OK-432, a streptococcal preparation.

Authors:  M Mihara; Y Ohsugi
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

4.  Inhibition of in vitro LAK generation by OK-432.

Authors:  M Yagita; E A Grimm
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Is There a Role for Bioactive Lipids in the Pathobiology of Diabetes Mellitus?

Authors:  Undurti N Das
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-02       Impact factor: 5.555

6.  Proliferative responses of peripheral blood mononuclear cells from psoriatic patients to T lymphocyte-stimulating cytokines (IL-2, IL-3, IL-4, and granulocyte-macrophage colony-stimulating factor) and OK-432.

Authors:  S Aiba; H Tagami
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

7.  The possible use of spleen cells for the adoptive immunotherapy of cancer patients.

Authors:  M Katano; H Yamamoto; E Kubota; M Nakamura; T Matsuo; F Nagumo; T Hisatsugu; T Katsuki; J Tadano
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

8.  Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy.

Authors:  T Misaki; Y Watanabe; Y Iida; A Hidaka; K Kasagi; H Fukushima; J Konishi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Induction of tumor growth inhibitory factor (TGIF) in human mononuclear cells by OK-432, a streptococcal preparation.

Authors:  M Katano; H Yamamoto; T Mizoguchi; T Hisatsugu
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy.

Authors:  Y Komada; S L Zhang; Y W Zhou; M Hanada; T Shibata; E Azuma; M Sakurai
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.